Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Atamyo Therapeutics

IND for ATA-200, a Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2C/R5 (LGMD2C/R5), cleared to proceed by FDA
From Atamyo Therapeutics
Via Business Wire
Atamyo Therapeutics Observes LGMD Awareness Day with Updates on Key Milestones in its Clinical Development of Gene Therapies for Patients Suffering from Limb-Girdle Muscular Dystrophies
From Atamyo Therapeutics
Via Business Wire
Atamyo Therapeutics to Provide Corporate Overviews and Updates on Its Pipeline Progress at 6 Upcoming Conferences in the US and Europe
From Atamyo Therapeutics
Via Business Wire
The Dion Foundation and Atamyo Therapeutics Announce a Partnership to Expand into the US Atamyo’s Clinical Trial of ATA-200 Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5
From Atamyo Therapeutics
Via Business Wire
Atamyo Therapeutics Obtains Regulatory Authorization in Europe to Initiate a Clinical Trial for ATA-200, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5
From Atamyo Therapeutics
Via Business Wire
First Clinical Results of ATA-100, a Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), Presented at ESGCT
From Atamyo Therapeutics
Via Business Wire
Atamyo Therapeutics Announces participation in Conferences and Key Scientific Communications on its LGMD programs
From Atamyo Therapeutics
Via Business Wire
ATA-200, Atamyo Therapeutics’ Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5, Reaches Key Milestones with the Filing of a Clinical Trial Application in Europe and a Non-Dilutive Financing from France 2030 Program
From Atamyo Therapeutics
Via Business Wire
IND for ATA-100, a Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), cleared to proceed by FDA
From Atamyo Therapeutics
Via Business Wire
Gene Therapy Pioneer Roger Hajjar, MD, Joins Atamyo Therapeutics Board of Directors
From Atamyo Therapeutics
Via Business Wire
Atamyo Therapeutics Announces First Patient Dosed with ATA-100 Gene Therapy in LGMD-R9 Clinical Trial
From Atamyo Therapeutics
Via Business Wire
Atamyo Therapeutics Announces Significant Milestones for ATA-100 and ATA-200, its Gene Therapy Programs to Treat Limb-Girdle Muscular Dystrophy 2I/R9 and 2C/R5
From Atamyo Therapeutics
Via Business Wire
Atamyo Therapeutics Reaches Significant Regulatory and Financial Milestones for ATA-100, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2I/R9
From Atamyo Therapeutics
Via Business Wire
Atamyo Therapeutics Obtains First Regulatory Authorization in Europe to Initiate a Clinical Trial for ATA-100, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2I/R9
From Atamyo Therapeutics
Via Business Wire
Atamyo Therapeutics Submits CTA in Europe for ATA-100, Its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2I/R9
From Atamyo Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.